PL4225351T1 - Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym - Google Patents

Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym

Info

Publication number
PL4225351T1
PL4225351T1 PL21880926.7T PL21880926T PL4225351T1 PL 4225351 T1 PL4225351 T1 PL 4225351T1 PL 21880926 T PL21880926 T PL 21880926T PL 4225351 T1 PL4225351 T1 PL 4225351T1
Authority
PL
Poland
Prior art keywords
active ingredient
therapueutic
vaccine
composition
combination
Prior art date
Application number
PL21880926.7T
Other languages
English (en)
Polish (pl)
Inventor
Tim Ioannides
Evangelos V. BADIAVAS
Original Assignee
Hpvvax, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/068,087 external-priority patent/US11813329B2/en
Application filed by Hpvvax, Llc filed Critical Hpvvax, Llc
Publication of PL4225351T1 publication Critical patent/PL4225351T1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21880926.7T 2020-10-12 2021-10-12 Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym PL4225351T1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/068,087 US11813329B2 (en) 2014-10-24 2020-10-12 Method and composition for treating cancer or skin lesion using a vaccine
PCT/US2021/054622 WO2022081604A1 (en) 2020-10-12 2021-10-12 Composition and method for treating cancer using a vaccine as a first therapueutic active ingredient in combination with a second active ingredient

Publications (1)

Publication Number Publication Date
PL4225351T1 true PL4225351T1 (pl) 2023-12-11

Family

ID=81208565

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21880926.7T PL4225351T1 (pl) 2020-10-12 2021-10-12 Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym

Country Status (16)

Country Link
EP (1) EP4225351A1 (es)
JP (1) JP2023546073A (es)
KR (1) KR20230117106A (es)
AU (1) AU2021360676A1 (es)
CA (1) CA3195478A1 (es)
CO (1) CO2023006083A2 (es)
CY (1) CY20232200001T2 (es)
DE (1) DE21880926T1 (es)
DK (1) DK4225351T1 (es)
ES (1) ES2962700T1 (es)
FI (1) FI4225351T1 (es)
HU (1) HUE21880926T1 (es)
IL (1) IL302098A (es)
MX (1) MX2023004285A (es)
PL (1) PL4225351T1 (es)
WO (1) WO2022081604A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10162480A1 (de) * 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
US20150148423A1 (en) * 2012-04-26 2015-05-28 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
US10799574B2 (en) * 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
MX2018012017A (es) * 2016-04-01 2019-07-04 Kite Pharma Inc Antigeno quimerico y receptores de celulas t y metodos de uso.
AU2017248259A1 (en) * 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions

Also Published As

Publication number Publication date
EP4225351A1 (en) 2023-08-16
WO2022081604A1 (en) 2022-04-21
JP2023546073A (ja) 2023-11-01
IL302098A (en) 2023-06-01
DK4225351T1 (da) 2023-10-23
AU2021360676A1 (en) 2023-06-15
ES2962700T1 (es) 2024-03-20
MX2023004285A (es) 2023-06-19
CA3195478A1 (en) 2022-04-21
CY20232200001T2 (el) 2024-02-16
HUE21880926T1 (hu) 2024-04-28
CO2023006083A2 (es) 2023-08-18
KR20230117106A (ko) 2023-08-07
FI4225351T1 (fi) 2023-10-20
DE21880926T1 (de) 2024-01-11

Similar Documents

Publication Publication Date Title
MX370624B (es) Composiciones que incluyen extractos de ampelopsis grossedentata y albizia julibrissin y métodos para uso.
ZA202201019B (en) Synergistic stable nitrogen fertilizer and preparation method
EP4043075C0 (en) KN-93 INTENDED FOR USE IN THE PREVENTION AND TREATMENT OF PSORIASIS
IL291601A (en) Neoglycoconjugates as vaccines and therapeutic tools
IL277315B (en) Method and preparations for treating the corona virus infection
NZ701133A (en) Composition for treating metabolic disorders
EP2583962A4 (en) NOVEL THIOURED OR NEW UREA DERIVATIVE, PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AIDS, CONTAINING THE SAME AS ACTIVE INGREDIENT
MX2015000884A (es) Composicion odontologica de papaina en gel para el tratamiento atraumatico de caries y metodo para prepararla.
PL4225351T1 (pl) Kompozycja i sposób leczenia nowotworu z zastosowaniem szczepionki jako pierwszego składnika terapeutycznie czynnego w połączeniu z drugim składnikiem czynnym
MX2022014763A (es) Composiciones de grapiprant y metodos para usar las mismas.
GB202306292D0 (en) Methods and compositions for cellular therapy
EP3419661A4 (en) METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN INJURY USING A VACCINE
EP4164628A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF CHRONIC PAIN
EP3727393A4 (en) METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANDIDA AURIS IN BLOOD
EP3616723A4 (en) METHOD FOR THE TREATMENT OF MYOPIA AND ITS APPLICATION IN THE PREPARATION OF A MEDICINE
GB202016863D0 (en) Microrna-29 compounds, compositions and uses in therapy
IL299950A (en) Superantigen conjugate for use in methods and compositions for the treatment of cancer
ZA202108650B (en) Pharmaceutical composition with anti-tumor efficacy, preparation method and uses thereof
GB202201935D0 (en) Methods and compositions for treating cancer in taxane-resistant patients
KR102627070B9 (ko) 미생물, 및 면역관문 억제제를 유효성분으로 포함하는, 고 당분 환경에서의 뇌종양 예방 또는 치료용 조성물
AU2021903484A0 (en) Methods and compositions for treating skin
GB202101665D0 (en) Methods and compositions for cellular therapy
GB202016659D0 (en) Methods and compositions for cellular therapy
ZA202212197B (en) Composition and method for suppressing sunburn and browning in plants and plant parts
GB202307609D0 (en) Methods and composition for kras modifications